全身化疗加吡柔比星热灌注化疗治疗晚期膀胱癌的疗效观察  

The Effects of Systemic Chemotherapy plus Pirarubicin Hyperthermic Perfusion Chemotherapy on Advanced Bladder Cancer

作　　者：李富林[1] 黄栋强[1] 黄锐[1] 

机构地区：[1]惠州市第一人民医院泌尿外科,广东惠州516000

出　　处：《肿瘤药学》2013年第5期382-384,398,共4页Anti-Tumor Pharmacy

摘　　要：目的探讨全身化疗加吡柔比星热灌注化疗治疗晚期膀胱癌的临床疗效和不良反应。方法将70例晚期膀胱癌病人随机分为研究组和对照组,每组35例。研究组的治疗方式为全身化疗加吡柔比星热灌注化疗,对照组的治疗方式为全身化疗加丝裂霉素热灌注化疗,比较两组患者的近期疗效、生活质量及不良反应发生率。结果化疗后研究组的总有效率、患者生活质量均显著高于对照组(P<0.05),两组患者的不良反应发生率无明显差异(P>0.05)。结论全身化疗加吡柔比星热灌注化疗治疗晚期膀胱癌疗效较好,患者的生活质量较高,不良反应可接受,值得临床推广。Objective To explore the clinical effect of systemic chemotherapy plus pirarubicin hyperthermic perfusion chem- otherapy on advanced bladder cancer and its adverse reactions. Methods Seventy patients with advanced bladder cancer were ran- domly divided into research group and control group, and each group had 35 patients. Patients in research group received systemic chemotherapy plus pirarubicin hyperthemaic perfusion chemotherapy; and patients in control group received systemic chemo- therapy plus nfitomycin hyperthermic perfusion chemotherapy. The short-term efficacy, life quality and adverse reactions of the two groups were compared. Results After chemotherapy, the total therapeutic effective rate and scores of patients＇ life quality of research group were significantly higher than those of the control group （P〈0.05）. There were no significantly differences be- tween the incidences of adverse reactions of the two groups （P〉 0.05）. Conclusions The treatment of systemic chemotherapy plus pirarubicin hyperthermic perfusion has better therapeutic effect on advanced bladder cancer. Patients got higher quality of life and acceptable adverse reactions. Therefore, this treatment is worthy of clinical application.

关 键 词：全身化疗 吡柔比星 热灌注化疗 晚期膀胱癌 

分 类 号：R737.14[医药卫生—肿瘤]